Lon Cardon

Lon Cardon, Ph.D., Chief Scientific Officer at BioMarin Pharmaceutical

Lon Cardon, Ph.D., is Chief Scientific Officer at BioMarin Pharmaceutical, a biopharmaceutical company specializing in novel therapies for rare genetic diseases. Lon joined BioMarin in September of 2017, following more than 25 years of research in discovering new genes for rare and common diseases and developing approaches to translate those discoveries into medicines. He was a senior academic in the UK and US for about half of his career, as a Full Professor at the University of Oxford and then the University of Washington and Fred Hutchinson Cancer Research Center. For the latter half of his career, he has worked in industry to translate those research findings, primarily as a Senior Vice President at GlaxoSmithKline, where he held executive leadership roles in several platform divisions and where he built an incubator for novel therapy areas. His groups created new research programs and academic partnering approaches in ophthalmology, rare diseases, and oligonucleotide and gene therapies, leading to the first European approval for an ex-vivo autologous cell/gene therapy medicine (ADA-SCID/Strimvelis) and new treatments for malaria and for new approaches to prevent neonate infection in the developing world. Lon was a Wellcome Trust Principal Fellow and is an elected Fellow of the UK’s Academy of Medical Sciences and the American Association for the Advancement of Science. He has authored more than 225 scientific publications and 15 books and chapters, mainly focused on genetics methodology and applications for rare and common diseases, ranging from Huntington’s disease to dyslexia.

Listen to the interview with Lon (published March 2018) https://mendelspod.com/podcasts/more-tools-box-lon-cardon-says-we%E2%80%...

New to Mendelspod?

We advance life science research, connecting people and ideas.
Register here to receive our newsletter.

or skip signup